Avalyn Pharma announced it will present updated long-term data from its ATLAS trial on AP01, an inhaled pirfenidone treatment for progressive pulmonary fibrosis, at the EULAR 2026 conference in London. The data covers up to four years of treatment, highlighting the drug's tolerability and potential to preserve lung function with fewer side effects compared to oral alternatives. This presentation supports Avalyn's goal to transform pulmonary fibrosis treatment through inhaled therapies. The company is also advancing other inhaled antifibrotic drugs in clinical trials.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
